Distribution agreement signed with General Medical W.L.L regarding distribution in Bahrain

Hemcheck Sweden AB has signed an exclusive distribution agreement with General Medical W.L.L (“General Medical”), a leading distributor of medical equipment in Bahrain. The agreement is valid until the end of April 2023, concerning the Bahraini market.

– General Medical is a well reputed and leading distributor, representing well known global companies in the Bahraini market. We are expanding our network in the Middle East and we look forward to work with General Medical in Bahrain. We hope that it will be a successful and long-term collaboration, says Joen Averstad, CEO of Hemcheck.

– We are very pleased to have signed this distributor agreement with Hemcheck. They have an innovative solution, and we believe there is good potential for the products in our market. We look forward to the collaboration, says Mohammed Merajuddin, Deputy General Manager, of General Medical.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About General Medical

General Medical W.L.L is the healthcare division of Intercol and was established in 1996. It is a leading player in the Kingdom of Bahrain with diversified activities and is marketing a wide range of diagnostic imaging equipment, biomedical equipment, diagnostics equipment, extracorporeal shock wave lithotripter (ESWL), pharmaceuticals, etc. General Medical also delivers projects for supply, installation and commissioning of hospital equipment and infrastructure. It is a partner in the local market to global companies such as Roche and Sysmex.

Read more at http://www.intercol.com/Verticals/HealthCare/ 

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

Important information

This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on April 19, 2021 at 13.00